A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02

AUTHORS

P S Hall, S R Lord, M Collinson, H Marshall, M Jones, C Lowe, H Howard, D Swinson, G Velikova, A Anthoney, R Roy, J Dent, S Cheeseman, K Last, M T Seymour

ABSTRACT

BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer. METHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1 : 1 : 1 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study recorded treatment choice for all patients with advanced GO cancer at trial centres. RESULTS: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115 received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4, 5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients (41%) had experienced a non-haematologic toxicity ⩾grade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for overall survival in patients alive at week 12 (logrank test P=0.0001). CONCLUSIONS: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for feasibility and randomised trials in the elderly and/or frail GO cancer population. More... »

PAGES

472

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2016.442

DOI

http://dx.doi.org/10.1038/bjc.2016.442

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006169380

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28095397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Frail Elderly", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Palliative Care", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Edinburgh", 
          "id": "https://www.grid.ac/institutes/grid.4305.2", 
          "name": [
            "Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hall", 
        "givenName": "P S", 
        "id": "sg:person.01232272557.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232272557.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lord", 
        "givenName": "S R", 
        "id": "sg:person.01133307242.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133307242.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collinson", 
        "givenName": "M", 
        "id": "sg:person.01335632056.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335632056.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marshall", 
        "givenName": "H", 
        "id": "sg:person.0624165205.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624165205.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "M", 
        "id": "sg:person.01066234003.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066234003.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NIHR Cancer Research Network Coordinating Centre, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lowe", 
        "givenName": "C", 
        "id": "sg:person.015377533065.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015377533065.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howard", 
        "givenName": "H", 
        "id": "sg:person.01347571305.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347571305.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Swinson", 
        "givenName": "D", 
        "id": "sg:person.01053344053.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053344053.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Velikova", 
        "givenName": "G", 
        "id": "sg:person.01145521343.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145521343.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Leeds", 
          "id": "https://www.grid.ac/institutes/grid.9909.9", 
          "name": [
            "Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anthoney", 
        "givenName": "A", 
        "id": "sg:person.0727202416.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727202416.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Castle Hill Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413509.a", 
          "name": [
            "Department of Oncology, Castle Hill Hospital, Hull, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roy", 
        "givenName": "R", 
        "id": "sg:person.01123510370.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123510370.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Huddersfield Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.417789.4", 
          "name": [
            "Department of Oncology, Huddersfield Royal Infirmary, Huddersfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dent", 
        "givenName": "J", 
        "id": "sg:person.010144257115.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010144257115.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "York Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417375.3", 
          "name": [
            "Department of Oncology, The York Hospital, York, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheeseman", 
        "givenName": "S", 
        "id": "sg:person.010741637515.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010741637515.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bradford Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.418447.a", 
          "name": [
            "Department of Oncology, The York Hospital, York, UK", 
            "Department of Oncology, Bradford Royal Infirmary, Bradford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Last", 
        "givenName": "K", 
        "id": "sg:person.01011236506.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011236506.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NIHR Cancer Research Network Coordinating Centre, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seymour", 
        "givenName": "M T", 
        "id": "sg:person.010065613017.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010065613017.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ejca.2005.08.044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000834573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011077422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa010957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012569804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa073149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014019609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.54.1011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014148840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0021-9681(87)90171-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020988115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2007.07.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023202393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03339847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025692851", 
          "https://doi.org/10.1007/bf03339847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-10-67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026717986", 
          "https://doi.org/10.1186/1471-2288-10-67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70096-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043828548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60399-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047680687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc0911925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049858409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.5.365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/026921558700100409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063799271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/026921558700100409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063799271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078314942", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083143992", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02", 
    "datePublishedReg": "2017-02-01", 
    "description": "BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer.\nMETHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1\u2009:\u20091\u2009:\u20091 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study recorded treatment choice for all patients with advanced GO cancer at trial centres.\nRESULTS: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115 received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4, 5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients (41%) had experienced a non-haematologic toxicity \u2a7egrade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for overall survival in patients alive at week 12 (logrank test P=0.0001).\nCONCLUSIONS: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for feasibility and randomised trials in the elderly and/or frail GO cancer population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2016.442", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "116"
      }
    ], 
    "name": "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)", 
    "pagination": "472", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1d63548314addba9a93ea63c379c13240be5d622903c58591270a297b44628d4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28095397"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2016.442"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006169380"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2016.442", 
      "https://app.dimensions.ai/details/publication/pub.1006169380"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000421.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2016442"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.442'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      21 PREDICATES      63 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2016.442 schema:about N12c7d65fe03449a398054faf5469174e
2 N13383e44fc424fb18c865ab9c1c29935
3 N13ade50c4dd8490e87b2911233c186f8
4 N1764de073dff44e59784bca2672e474e
5 N2de9123cd2524a50b6ba3311a44af921
6 N41d915b269074ad596431bd65e77e2cc
7 N4e5403cf56514b438f34dc13e3e52432
8 N57200e24542449e79b7dfc4e1439382f
9 N6c48b62cad1247b7a46d028cf980f723
10 Nab01add41d244561a3bd6f7aef7e9da9
11 Nb9333e487f5346f5925496e688d6ddae
12 Nbfb6fe18546149a68508d22dc74a9f12
13 Nc29266ac161446d59ad1cdaabbeed7c7
14 Nd685f36e14df45a9b82fb4a74fba1931
15 Nd7277070b21346d287350d97355dea1c
16 Ndb832a924474425b9c53d4e766f04f60
17 Nf772eb0d4a7e4d87850daf210cab3edd
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Neeeae2a46c2d49b4a012a7e6aa388aef
21 schema:citation sg:pub.10.1007/bf03339847
22 sg:pub.10.1186/1471-2288-10-67
23 https://app.dimensions.ai/details/publication/pub.1078314942
24 https://app.dimensions.ai/details/publication/pub.1083143992
25 https://doi.org/10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n
26 https://doi.org/10.1016/0021-9681(87)90171-8
27 https://doi.org/10.1016/j.ejca.2005.08.044
28 https://doi.org/10.1016/j.ejca.2007.07.005
29 https://doi.org/10.1016/s0140-6736(11)60399-1
30 https://doi.org/10.1016/s1470-2045(13)70096-2
31 https://doi.org/10.1056/nejmc0911925
32 https://doi.org/10.1056/nejmoa010957
33 https://doi.org/10.1056/nejmoa073149
34 https://doi.org/10.1093/jnci/85.5.365
35 https://doi.org/10.1177/026921558700100409
36 https://doi.org/10.1200/jco.1999.17.8.2412
37 https://doi.org/10.1200/jco.2013.54.1011
38 schema:datePublished 2017-02
39 schema:datePublishedReg 2017-02-01
40 schema:description BACKGROUND: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced gastroesophageal (GO) cancer. METHODS: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a 1 : 1 : 1 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X) (all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study recorded treatment choice for all patients with advanced GO cancer at trial centres. RESULTS: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115 received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4, 5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients (41%) had experienced a non-haematologic toxicity ⩾grade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for overall survival in patients alive at week 12 (logrank test P=0.0001). CONCLUSIONS: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for feasibility and randomised trials in the elderly and/or frail GO cancer population.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree true
44 schema:isPartOf N2aaf6f9027b84aa1b6e82b672d603218
45 N5d0442a18af348d88111c5001127c588
46 sg:journal.1017082
47 schema:name A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
48 schema:pagination 472
49 schema:productId N00116003b2ca4ee19da2e5be929b47b3
50 N46c8821e3bdc4dec879508dc42e4d1d8
51 N4f4c5657262a4bcc9f5146bf669eb059
52 N98c4887a6ff0407398185d6dd0ed52ef
53 Ncf10efc5ebff436cb4fe134ff2661214
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006169380
55 https://doi.org/10.1038/bjc.2016.442
56 schema:sdDatePublished 2019-04-11T00:03
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N0e1b09e17c5b4c1d8d8f1363fa30bb98
59 schema:url https://www.nature.com/articles/bjc2016442
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N00116003b2ca4ee19da2e5be929b47b3 schema:name doi
64 schema:value 10.1038/bjc.2016.442
65 rdf:type schema:PropertyValue
66 N00b3e67ae17743cb8f4fd10a478b4b46 rdf:first sg:person.0727202416.01
67 rdf:rest N72e275774af244ea8955820c831cbd63
68 N0e1b09e17c5b4c1d8d8f1363fa30bb98 schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 N11ff3d8165ae41f2911b7547ac467fb2 schema:name NIHR Cancer Research Network Coordinating Centre, Leeds, UK
71 rdf:type schema:Organization
72 N12c7d65fe03449a398054faf5469174e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Male
74 rdf:type schema:DefinedTerm
75 N13383e44fc424fb18c865ab9c1c29935 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Palliative Care
77 rdf:type schema:DefinedTerm
78 N13ade50c4dd8490e87b2911233c186f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Fluorouracil
80 rdf:type schema:DefinedTerm
81 N1439a4c4a04d423198217f5aa86fbef7 rdf:first sg:person.015377533065.48
82 rdf:rest N8af0aea7a9f74caf9ef8ec5b550454db
83 N1764de073dff44e59784bca2672e474e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Adenocarcinoma
85 rdf:type schema:DefinedTerm
86 N2445e17c5aab4647a8f6845d59644c86 rdf:first sg:person.0624165205.08
87 rdf:rest Nad0b0c8caa534380a438cd0f7fe69b78
88 N2aaf6f9027b84aa1b6e82b672d603218 schema:issueNumber 4
89 rdf:type schema:PublicationIssue
90 N2de9123cd2524a50b6ba3311a44af921 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Feasibility Studies
92 rdf:type schema:DefinedTerm
93 N2fff27a809fd46f8b7b93e901f00c070 rdf:first sg:person.01133307242.30
94 rdf:rest Nc14e31447a7b44819fc8d2e711a9e683
95 N41d915b269074ad596431bd65e77e2cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Organoplatinum Compounds
97 rdf:type schema:DefinedTerm
98 N46c8821e3bdc4dec879508dc42e4d1d8 schema:name pubmed_id
99 schema:value 28095397
100 rdf:type schema:PropertyValue
101 N4e5403cf56514b438f34dc13e3e52432 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Aged, 80 and over
103 rdf:type schema:DefinedTerm
104 N4f4c5657262a4bcc9f5146bf669eb059 schema:name readcube_id
105 schema:value 1d63548314addba9a93ea63c379c13240be5d622903c58591270a297b44628d4
106 rdf:type schema:PropertyValue
107 N57200e24542449e79b7dfc4e1439382f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Humans
109 rdf:type schema:DefinedTerm
110 N5d0442a18af348d88111c5001127c588 schema:volumeNumber 116
111 rdf:type schema:PublicationVolume
112 N60f40da01c9e40b490405bc38f655ad8 schema:name NIHR Cancer Research Network Coordinating Centre, Leeds, UK
113 rdf:type schema:Organization
114 N6c48b62cad1247b7a46d028cf980f723 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Deoxycytidine
116 rdf:type schema:DefinedTerm
117 N72e275774af244ea8955820c831cbd63 rdf:first sg:person.01123510370.80
118 rdf:rest Ne10032d4d046467e80b1e347020828ad
119 N81c0c8d64fa84437ba6648d5d90f8b99 rdf:first sg:person.01053344053.92
120 rdf:rest N9216a2b745e04e12b320ce46bd2cf602
121 N8af0aea7a9f74caf9ef8ec5b550454db rdf:first sg:person.01347571305.92
122 rdf:rest N81c0c8d64fa84437ba6648d5d90f8b99
123 N9216a2b745e04e12b320ce46bd2cf602 rdf:first sg:person.01145521343.84
124 rdf:rest N00b3e67ae17743cb8f4fd10a478b4b46
125 N98c4887a6ff0407398185d6dd0ed52ef schema:name dimensions_id
126 schema:value pub.1006169380
127 rdf:type schema:PropertyValue
128 Nab01add41d244561a3bd6f7aef7e9da9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Frail Elderly
130 rdf:type schema:DefinedTerm
131 Nad0b0c8caa534380a438cd0f7fe69b78 rdf:first sg:person.01066234003.22
132 rdf:rest N1439a4c4a04d423198217f5aa86fbef7
133 Nb5981f53bc8c4078a8ca9294b8e5b30a rdf:first sg:person.01011236506.59
134 rdf:rest Nc52d4d9197c243e2a2569edcbf665763
135 Nb9333e487f5346f5925496e688d6ddae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Female
137 rdf:type schema:DefinedTerm
138 Nbfb6fe18546149a68508d22dc74a9f12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Capecitabine
140 rdf:type schema:DefinedTerm
141 Nc14e31447a7b44819fc8d2e711a9e683 rdf:first sg:person.01335632056.21
142 rdf:rest N2445e17c5aab4647a8f6845d59644c86
143 Nc242f9e3963540c5bb53dd479f908b22 rdf:first sg:person.010741637515.42
144 rdf:rest Nb5981f53bc8c4078a8ca9294b8e5b30a
145 Nc29266ac161446d59ad1cdaabbeed7c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 Nc52d4d9197c243e2a2569edcbf665763 rdf:first sg:person.010065613017.91
149 rdf:rest rdf:nil
150 Ncf10efc5ebff436cb4fe134ff2661214 schema:name nlm_unique_id
151 schema:value 0370635
152 rdf:type schema:PropertyValue
153 Nd685f36e14df45a9b82fb4a74fba1931 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Disease Progression
155 rdf:type schema:DefinedTerm
156 Nd7277070b21346d287350d97355dea1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Epirubicin
158 rdf:type schema:DefinedTerm
159 Ndb832a924474425b9c53d4e766f04f60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Esophageal Neoplasms
161 rdf:type schema:DefinedTerm
162 Ne10032d4d046467e80b1e347020828ad rdf:first sg:person.010144257115.34
163 rdf:rest Nc242f9e3963540c5bb53dd479f908b22
164 Neeeae2a46c2d49b4a012a7e6aa388aef rdf:first sg:person.01232272557.00
165 rdf:rest N2fff27a809fd46f8b7b93e901f00c070
166 Nf772eb0d4a7e4d87850daf210cab3edd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Antineoplastic Combined Chemotherapy Protocols
168 rdf:type schema:DefinedTerm
169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
170 schema:name Medical and Health Sciences
171 rdf:type schema:DefinedTerm
172 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
173 schema:name Oncology and Carcinogenesis
174 rdf:type schema:DefinedTerm
175 sg:journal.1017082 schema:issn 0007-0920
176 1532-1827
177 schema:name British Journal of Cancer
178 rdf:type schema:Periodical
179 sg:person.010065613017.91 schema:affiliation N11ff3d8165ae41f2911b7547ac467fb2
180 schema:familyName Seymour
181 schema:givenName M T
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010065613017.91
183 rdf:type schema:Person
184 sg:person.01011236506.59 schema:affiliation https://www.grid.ac/institutes/grid.418447.a
185 schema:familyName Last
186 schema:givenName K
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011236506.59
188 rdf:type schema:Person
189 sg:person.010144257115.34 schema:affiliation https://www.grid.ac/institutes/grid.417789.4
190 schema:familyName Dent
191 schema:givenName J
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010144257115.34
193 rdf:type schema:Person
194 sg:person.01053344053.92 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
195 schema:familyName Swinson
196 schema:givenName D
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053344053.92
198 rdf:type schema:Person
199 sg:person.01066234003.22 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
200 schema:familyName Jones
201 schema:givenName M
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066234003.22
203 rdf:type schema:Person
204 sg:person.010741637515.42 schema:affiliation https://www.grid.ac/institutes/grid.417375.3
205 schema:familyName Cheeseman
206 schema:givenName S
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010741637515.42
208 rdf:type schema:Person
209 sg:person.01123510370.80 schema:affiliation https://www.grid.ac/institutes/grid.413509.a
210 schema:familyName Roy
211 schema:givenName R
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123510370.80
213 rdf:type schema:Person
214 sg:person.01133307242.30 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
215 schema:familyName Lord
216 schema:givenName S R
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133307242.30
218 rdf:type schema:Person
219 sg:person.01145521343.84 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
220 schema:familyName Velikova
221 schema:givenName G
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145521343.84
223 rdf:type schema:Person
224 sg:person.01232272557.00 schema:affiliation https://www.grid.ac/institutes/grid.4305.2
225 schema:familyName Hall
226 schema:givenName P S
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232272557.00
228 rdf:type schema:Person
229 sg:person.01335632056.21 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
230 schema:familyName Collinson
231 schema:givenName M
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335632056.21
233 rdf:type schema:Person
234 sg:person.01347571305.92 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
235 schema:familyName Howard
236 schema:givenName H
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347571305.92
238 rdf:type schema:Person
239 sg:person.015377533065.48 schema:affiliation N60f40da01c9e40b490405bc38f655ad8
240 schema:familyName Lowe
241 schema:givenName C
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015377533065.48
243 rdf:type schema:Person
244 sg:person.0624165205.08 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
245 schema:familyName Marshall
246 schema:givenName H
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624165205.08
248 rdf:type schema:Person
249 sg:person.0727202416.01 schema:affiliation https://www.grid.ac/institutes/grid.9909.9
250 schema:familyName Anthoney
251 schema:givenName A
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727202416.01
253 rdf:type schema:Person
254 sg:pub.10.1007/bf03339847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025692851
255 https://doi.org/10.1007/bf03339847
256 rdf:type schema:CreativeWork
257 sg:pub.10.1186/1471-2288-10-67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026717986
258 https://doi.org/10.1186/1471-2288-10-67
259 rdf:type schema:CreativeWork
260 https://app.dimensions.ai/details/publication/pub.1078314942 schema:CreativeWork
261 https://app.dimensions.ai/details/publication/pub.1083143992 schema:CreativeWork
262 https://doi.org/10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1011077422
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1016/0021-9681(87)90171-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020988115
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/j.ejca.2005.08.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000834573
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/j.ejca.2007.07.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023202393
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/s0140-6736(11)60399-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047680687
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/s1470-2045(13)70096-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043828548
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1056/nejmc0911925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049858409
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1056/nejmoa010957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012569804
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1056/nejmoa073149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014019609
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1093/jnci/85.5.365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818446
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1177/026921558700100409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063799271
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1200/jco.1999.17.8.2412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549860
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1200/jco.2013.54.1011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014148840
287 rdf:type schema:CreativeWork
288 https://www.grid.ac/institutes/grid.413509.a schema:alternateName Castle Hill Hospital
289 schema:name Department of Oncology, Castle Hill Hospital, Hull, UK
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.417375.3 schema:alternateName York Hospital
292 schema:name Department of Oncology, The York Hospital, York, UK
293 rdf:type schema:Organization
294 https://www.grid.ac/institutes/grid.417789.4 schema:alternateName Huddersfield Royal Infirmary
295 schema:name Department of Oncology, Huddersfield Royal Infirmary, Huddersfield, UK
296 rdf:type schema:Organization
297 https://www.grid.ac/institutes/grid.418447.a schema:alternateName Bradford Royal Infirmary
298 schema:name Department of Oncology, Bradford Royal Infirmary, Bradford, UK
299 Department of Oncology, The York Hospital, York, UK
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.4305.2 schema:alternateName University of Edinburgh
302 schema:name Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
305 schema:name Department of Oncology, University of Oxford, Oxford, UK
306 rdf:type schema:Organization
307 https://www.grid.ac/institutes/grid.9909.9 schema:alternateName University of Leeds
308 schema:name Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
309 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...